These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 22629478

  • 21. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
    Rai K, Cuypers B, Bhattarai NR, Uranw S, Berg M, Ostyn B, Dujardin JC, Rijal S, Vanaerschot M.
    mBio; 2013 Oct 08; 4(5):e00611-13. PubMed ID: 24105765
    [Abstract] [Full Text] [Related]

  • 22. Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.
    Hendrickx S, Boulet G, Mondelaers A, Dujardin JC, Rijal S, Lachaud L, Cos P, Delputte P, Maes L.
    Parasitol Res; 2014 May 08; 113(5):1875-81. PubMed ID: 24615359
    [Abstract] [Full Text] [Related]

  • 23. In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
    Hendrickx S, Mondelaers A, Eberhardt E, Delputte P, Cos P, Maes L.
    Antimicrob Agents Chemother; 2015 Aug 08; 59(8):4714-8. PubMed ID: 26014955
    [Abstract] [Full Text] [Related]

  • 24. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
    Burza S, Sinha PK, Mahajan R, Sanz MG, Lima MA, Mitra G, Verma N, Das P.
    PLoS Negl Trop Dis; 2014 Aug 08; 8(1):e2611. PubMed ID: 24392171
    [Abstract] [Full Text] [Related]

  • 25. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB, Das P.
    Am J Trop Med Hyg; 2009 Mar 08; 80(3):336-8. PubMed ID: 19270277
    [Abstract] [Full Text] [Related]

  • 26. Evaluating drug resistance in visceral leishmaniasis: the challenges.
    Hendrickx S, Guerin PJ, Caljon G, Croft SL, Maes L.
    Parasitology; 2018 Apr 08; 145(4):453-463. PubMed ID: 27866478
    [Abstract] [Full Text] [Related]

  • 27. Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.
    Pandey K, Das VN, Singh D, Das S, Lal CS, Verma N, Bimal S, Topno RK, Siddiqui NA, Verma RB, Sinha PK, Das P.
    J Clin Microbiol; 2012 Apr 08; 50(4):1478-9. PubMed ID: 22278840
    [Abstract] [Full Text] [Related]

  • 28. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
    Kumar D, Kulshrestha A, Singh R, Salotra P.
    Antimicrob Agents Chemother; 2009 Feb 08; 53(2):835-8. PubMed ID: 19015344
    [Abstract] [Full Text] [Related]

  • 29. Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden.
    Vanaerschot M, De Doncker S, Rijal S, Maes L, Dujardin JC, Decuypere S.
    PLoS One; 2011 Feb 08; 6(8):e23120. PubMed ID: 21829701
    [Abstract] [Full Text] [Related]

  • 30. Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection.
    Hendrickx S, Van Bockstal L, Bulté D, Mondelaers A, Aslan H, Rivas L, Maes L, Caljon G.
    Parasit Vectors; 2020 Feb 22; 13(1):96. PubMed ID: 32087758
    [Abstract] [Full Text] [Related]

  • 31. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
    Saurabh S, Roy P, Pandey DK, Ray D, Tarak S, Pandey R, Kumar D, Jamil S, Paulraj A, Kumar A, Dutta S.
    J Vector Borne Dis; 2020 Feb 22; 57(2):161-169. PubMed ID: 34290161
    [Abstract] [Full Text] [Related]

  • 32. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
    Zijlstra EE, Alves F, Rijal S, Arana B, Alvar J.
    PLoS Negl Trop Dis; 2017 Nov 22; 11(11):e0005877. PubMed ID: 29145397
    [Abstract] [Full Text] [Related]

  • 33. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
    Goyal V, Das VNR, Singh SN, Singh RS, Pandey K, Verma N, Hightower A, Rijal S, Das P, Alvar J, Bern C, Alves F.
    PLoS Negl Trop Dis; 2020 Jul 22; 14(7):e0008429. PubMed ID: 32687498
    [Abstract] [Full Text] [Related]

  • 34. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
    Hendrickx S, Eberhardt E, Mondelaers A, Rijal S, Bhattarai NR, Dujardin JC, Delputte P, Cos P, Maes L.
    J Antimicrob Chemother; 2015 Nov 22; 70(11):3023-6. PubMed ID: 26253089
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Chemotherapeutics of visceral leishmaniasis: present and future developments.
    Sundar S, Singh A.
    Parasitology; 2018 Apr 22; 145(4):481-489. PubMed ID: 29215329
    [Abstract] [Full Text] [Related]

  • 37. Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia.
    Palić S, Chu WY, Sundar S, Mondal D, Das P, Pandey K, Raja S, Rijal S, Roseboom IC, Hamadeh A, Malik PRV, Beijnen JH, Huitema ADR, Sjögren E, Alves F, Dorlo TPC.
    J Antimicrob Chemother; 2024 Jul 01; 79(7):1547-1554. PubMed ID: 38727613
    [Abstract] [Full Text] [Related]

  • 38. Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
    Hasnain G, Shomik MS, Ghosh P, Rashid MO, Hossain S, Hamano S, Mondal D.
    Am J Trop Med Hyg; 2016 Dec 07; 95(6):1383-1385. PubMed ID: 27672208
    [Abstract] [Full Text] [Related]

  • 39. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
    Singh R, Kumar D, Ramesh V, Negi NS, Singh S, Salotra P.
    J Infect Dis; 2006 Aug 01; 194(3):302-6. PubMed ID: 16826477
    [Abstract] [Full Text] [Related]

  • 40. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.
    Pijpers J, den Boer ML, Essink DR, Ritmeijer K.
    PLoS Negl Trop Dis; 2019 Feb 01; 13(2):e0007173. PubMed ID: 30742620
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.